More than half of the adults with anxiety disorders have a childhood history of psychiatric illness, and more than one-third had anxiety disorders at ages 11–15. This continuity emerged from longitudinal assessments of the individuals born during 1972–1973 in Dunedin, New Zealand. Gregory et al. (p. 301) report that among those with anxiety diagnoses at age 32, an early history of depression was also common. For children and adolescents with generalized anxiety disorder, Rynn et al. (p. 290) found that extended-release venlafaxine is an effective treatment. Combined data on 313 participants in two placebo-controlled trials demonstrated that 69% of the venlafaxine patients were greatly improved at the end of 8 weeks, compared to 48% of the placebo patients. The improvements occurred in both children (ages 6–11) and adolescents (ages 12–17). The venlafaxine and placebo groups each had one case of suicidal thoughts or attempts. Extended-release venlafaxine had effects on weight, height, cholesterol level, heart rate, and blood pressure.